<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332188</url>
  </required_header>
  <id_info>
    <org_study_id>11-100-0004</org_study_id>
    <nct_id>NCT01332188</nct_id>
  </id_info>
  <brief_title>Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model</brief_title>
  <acronym>AC-170</acronym>
  <official_title>A Single Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Efficacy of Three Different Concentrations of Cetirizine (0.05%, 0.1%, and 0.24%) Ophthalmic Solution Versus Vehicle in the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model (CAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aciex Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aciex Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of different concentrations of AC-170
      compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in
      the conjunctival allergen challenge (CAC) Model.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosis at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosis at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosis at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelid Swelling at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelid Swelling at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelid Swelling at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tearing at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tearing at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tearing at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinorrhea at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinorrhea at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinorrhea at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Pruritus at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Pruritus at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Pruritus at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ear or Palate Pruritus at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ear or Palate Pruritus at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Congestion at Onset of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Congestion at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Congestion at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Composite Score at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Composite Score at Duration of Action (24 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Composite Score at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Study Medication at Visit 3A</measure>
    <time_frame>upon instillation, 1 minute and 2 minutes post instillation</time_frame>
    <description>Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome..</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>AC-170 0.05%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-170 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-170 0.24%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-170 0%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 0.05%</intervention_name>
    <description>1 drop in each eye at 3 separate times during a 21 day period</description>
    <arm_group_label>AC-170 0.05%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 0.1%</intervention_name>
    <description>1 drop in each eye at 3 separate times during a 21 day period</description>
    <arm_group_label>AC-170 0.1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 0.24%</intervention_name>
    <description>1 drop in each eye at 3 separate times during a 21 day period</description>
    <arm_group_label>AC-170 0.24%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 0%</intervention_name>
    <description>1 drop in each eye at 3 separate times during a 21 day period</description>
    <arm_group_label>AC-170 0%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive bilateral conjunctival allergen challenge (CAC) reaction

        Exclusion Criteria:

          -  Known contraindications or sensitivities to the study medication or its components.

          -  Any ocular condition that, in the opinion of the investigator, could affect the
             subjects safety or trial parameters.

          -  Use of disallowed medications during the period indicated prior to the study
             enrollment or during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail L Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andover Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ora, Inc.</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <results_first_submitted>June 28, 2017</results_first_submitted>
  <results_first_submitted_qc>July 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 30, 2017</results_first_posted>
  <disposition_first_submitted>July 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 19, 2012</disposition_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from one site in the US.</recruitment_details>
      <pre_assignment_details>101 subjects were enrolled, 7 subjects discontinued, and 94 subjects completed the study. The 101 subjects that met all inclusion criteria and none of the exclusion criteria were randomized to receive AC-170 0.05%, AC-170 0.1%, AC-170 0.24% or AC-170 0%.
Note: All solutions were “early formulations” and not the final to-be-marketed formulation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AC-170 0.05%</title>
          <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
        <group group_id="P2">
          <title>AC-170 0.1%</title>
          <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
        <group group_id="P3">
          <title>AC-170 0.24%</title>
          <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
        <group group_id="P4">
          <title>AC-170 0%</title>
          <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AC-170 0.05%</title>
          <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
        <group group_id="B2">
          <title>AC-170 0.1%</title>
          <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
        <group group_id="B3">
          <title>AC-170 0.24%</title>
          <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
        <group group_id="B4">
          <title>AC-170 0%</title>
          <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="13.58"/>
                    <measurement group_id="B2" value="43.1" spread="13.5"/>
                    <measurement group_id="B3" value="38.9" spread="12.53"/>
                    <measurement group_id="B4" value="38.1" spread="14.12"/>
                    <measurement group_id="B5" value="41.4" spread="13.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="0.924"/>
                    <measurement group_id="O2" value="2.00" spread="0.771"/>
                    <measurement group_id="O3" value="1.65" spread="0.963"/>
                    <measurement group_id="O4" value="2.48" spread="0.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="1.019"/>
                    <measurement group_id="O2" value="2.04" spread="0.889"/>
                    <measurement group_id="O3" value="1.74" spread="0.843"/>
                    <measurement group_id="O4" value="2.55" spread="0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.907"/>
                    <measurement group_id="O2" value="1.87" spread="0.913"/>
                    <measurement group_id="O3" value="1.75" spread="0.910"/>
                    <measurement group_id="O4" value="2.27" spread="0.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.849"/>
                    <measurement group_id="O2" value="1.78" spread="0.873"/>
                    <measurement group_id="O3" value="1.90" spread="0.804"/>
                    <measurement group_id="O4" value="2.24" spread="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.711"/>
                    <measurement group_id="O2" value="1.92" spread="0.883"/>
                    <measurement group_id="O3" value="2.17" spread="0.819"/>
                    <measurement group_id="O4" value="2.24" spread="0.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.774"/>
                    <measurement group_id="O2" value="1.78" spread="0.988"/>
                    <measurement group_id="O3" value="1.97" spread="0.833"/>
                    <measurement group_id="O4" value="2.08" spread="0.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.804"/>
                    <measurement group_id="O2" value="0.84" spread="0.800"/>
                    <measurement group_id="O3" value="0.91" spread="0.810"/>
                    <measurement group_id="O4" value="1.94" spread="0.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.778"/>
                    <measurement group_id="O2" value="1.09" spread="0.941"/>
                    <measurement group_id="O3" value="1.07" spread="0.840"/>
                    <measurement group_id="O4" value="2.09" spread="0.850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.789"/>
                    <measurement group_id="O2" value="1.07" spread="0.929"/>
                    <measurement group_id="O3" value="0.97" spread="0.843"/>
                    <measurement group_id="O4" value="1.94" spread="0.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.634"/>
                    <measurement group_id="O2" value="1.59" spread="0.624"/>
                    <measurement group_id="O3" value="1.45" spread="0.489"/>
                    <measurement group_id="O4" value="1.79" spread="0.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.606"/>
                    <measurement group_id="O2" value="1.65" spread="0.711"/>
                    <measurement group_id="O3" value="1.61" spread="0.545"/>
                    <measurement group_id="O4" value="1.91" spread="0.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.696"/>
                    <measurement group_id="O2" value="1.58" spread="0.721"/>
                    <measurement group_id="O3" value="1.56" spread="0.634"/>
                    <measurement group_id="O4" value="1.88" spread="0.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.635"/>
                    <measurement group_id="O2" value="1.38" spread="0.668"/>
                    <measurement group_id="O3" value="1.71" spread="0.628"/>
                    <measurement group_id="O4" value="1.70" spread="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.617"/>
                    <measurement group_id="O2" value="1.59" spread="0.663"/>
                    <measurement group_id="O3" value="1.85" spread="0.608"/>
                    <measurement group_id="O4" value="1.90" spread="0.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.617"/>
                    <measurement group_id="O2" value="1.54" spread="0.677"/>
                    <measurement group_id="O3" value="1.79" spread="0.713"/>
                    <measurement group_id="O4" value="1.76" spread="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.663"/>
                    <measurement group_id="O2" value="1.45" spread="0.812"/>
                    <measurement group_id="O3" value="1.66" spread="0.718"/>
                    <measurement group_id="O4" value="1.88" spread="0.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.670"/>
                    <measurement group_id="O2" value="1.67" spread="0.821"/>
                    <measurement group_id="O3" value="1.83" spread="0.680"/>
                    <measurement group_id="O4" value="1.96" spread="0.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.648"/>
                    <measurement group_id="O2" value="1.67" spread="0.868"/>
                    <measurement group_id="O3" value="1.79" spread="0.717"/>
                    <measurement group_id="O4" value="1.97" spread="0.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.708"/>
                    <measurement group_id="O2" value="1.53" spread="0.758"/>
                    <measurement group_id="O3" value="1.34" spread="0.684"/>
                    <measurement group_id="O4" value="1.81" spread="0.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.707"/>
                    <measurement group_id="O2" value="1.65" spread="0.842"/>
                    <measurement group_id="O3" value="1.52" spread="0.732"/>
                    <measurement group_id="O4" value="1.99" spread="0.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.703"/>
                    <measurement group_id="O2" value="1.65" spread="0.878"/>
                    <measurement group_id="O3" value="1.53" spread="0.788"/>
                    <measurement group_id="O4" value="1.95" spread="0.573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.730"/>
                    <measurement group_id="O2" value="1.22" spread="0.686"/>
                    <measurement group_id="O3" value="1.50" spread="0.633"/>
                    <measurement group_id="O4" value="1.55" spread="0.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.596"/>
                    <measurement group_id="O2" value="1.47" spread="0.723"/>
                    <measurement group_id="O3" value="1.74" spread="0.716"/>
                    <measurement group_id="O4" value="1.77" spread="0.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.617"/>
                    <measurement group_id="O2" value="1.47" spread="0.701"/>
                    <measurement group_id="O3" value="1.65" spread="0.736"/>
                    <measurement group_id="O4" value="1.65" spread="0.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT). Number of analyzed subjects differ due to subject discontinuation during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT). Number of analyzed subjects differ due to subject discontinuation during the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.689"/>
                    <measurement group_id="O2" value="1.24" spread="0.867"/>
                    <measurement group_id="O3" value="1.27" spread="0.858"/>
                    <measurement group_id="O4" value="1.67" spread="0.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="0.749"/>
                    <measurement group_id="O2" value="1.51" spread="0.861"/>
                    <measurement group_id="O3" value="1.64" spread="0.669"/>
                    <measurement group_id="O4" value="1.77" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.647"/>
                    <measurement group_id="O2" value="1.52" spread="0.952"/>
                    <measurement group_id="O3" value="1.73" spread="0.622"/>
                    <measurement group_id="O4" value="1.79" spread="0.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.602"/>
                    <measurement group_id="O2" value="1.74" spread="0.690"/>
                    <measurement group_id="O3" value="1.57" spread="0.497"/>
                    <measurement group_id="O4" value="1.90" spread="0.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.639"/>
                    <measurement group_id="O2" value="1.77" spread="0.757"/>
                    <measurement group_id="O3" value="1.69" spread="0.605"/>
                    <measurement group_id="O4" value="2.02" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.629"/>
                    <measurement group_id="O2" value="1.73" spread="0.797"/>
                    <measurement group_id="O3" value="1.69" spread="0.647"/>
                    <measurement group_id="O4" value="1.97" spread="0.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.590"/>
                    <measurement group_id="O2" value="1.37" spread="0.681"/>
                    <measurement group_id="O3" value="1.73" spread="0.616"/>
                    <measurement group_id="O4" value="1.80" spread="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.585"/>
                    <measurement group_id="O2" value="1.63" spread="0.700"/>
                    <measurement group_id="O3" value="1.90" spread="0.657"/>
                    <measurement group_id="O4" value="2.00" spread="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.579"/>
                    <measurement group_id="O2" value="1.60" spread="0.688"/>
                    <measurement group_id="O3" value="1.87" spread="0.696"/>
                    <measurement group_id="O4" value="1.85" spread="0.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="0.644"/>
                    <measurement group_id="O2" value="1.49" spread="0.782"/>
                    <measurement group_id="O3" value="1.64" spread="0.744"/>
                    <measurement group_id="O4" value="1.93" spread="0.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.652"/>
                    <measurement group_id="O2" value="1.73" spread="0.803"/>
                    <measurement group_id="O3" value="1.98" spread="0.698"/>
                    <measurement group_id="O4" value="2.01" spread="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="0.577"/>
                    <measurement group_id="O2" value="1.72" spread="0.861"/>
                    <measurement group_id="O3" value="1.88" spread="0.644"/>
                    <measurement group_id="O4" value="2.04" spread="0.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemosis at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Chemosis at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.553"/>
                    <measurement group_id="O2" value="0.58" spread="0.406"/>
                    <measurement group_id="O3" value="0.53" spread="0.292"/>
                    <measurement group_id="O4" value="0.72" spread="0.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.557"/>
                    <measurement group_id="O2" value="0.70" spread="0.545"/>
                    <measurement group_id="O3" value="0.60" spread="0.354"/>
                    <measurement group_id="O4" value="0.99" spread="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.644"/>
                    <measurement group_id="O2" value="0.72" spread="0.583"/>
                    <measurement group_id="O3" value="0.71" spread="0.460"/>
                    <measurement group_id="O4" value="1.00" spread="0.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemosis at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Chemosis at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.478"/>
                    <measurement group_id="O2" value="0.52" spread="0.279"/>
                    <measurement group_id="O3" value="0.55" spread="0.298"/>
                    <measurement group_id="O4" value="0.68" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.612"/>
                    <measurement group_id="O2" value="0.64" spread="0.396"/>
                    <measurement group_id="O3" value="0.77" spread="0.433"/>
                    <measurement group_id="O4" value="0.81" spread="0.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.647"/>
                    <measurement group_id="O2" value="0.71" spread="0.419"/>
                    <measurement group_id="O3" value="0.84" spread="0.572"/>
                    <measurement group_id="O4" value="0.90" spread="0.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemosis at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Chemosis at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.232"/>
                    <measurement group_id="O2" value="0.43" spread="0.293"/>
                    <measurement group_id="O3" value="0.54" spread="0.277"/>
                    <measurement group_id="O4" value="0.74" spread="0.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.423"/>
                    <measurement group_id="O2" value="0.52" spread="0.314"/>
                    <measurement group_id="O3" value="0.79" spread="0.456"/>
                    <measurement group_id="O4" value="0.80" spread="0.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.403"/>
                    <measurement group_id="O2" value="0.53" spread="0.363"/>
                    <measurement group_id="O3" value="0.76" spread="0.399"/>
                    <measurement group_id="O4" value="0.88" spread="0.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eyelid Swelling at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Eyelid Swelling at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.75"/>
                    <measurement group_id="O2" value="0.8" spread="0.66"/>
                    <measurement group_id="O3" value="0.8" spread="0.66"/>
                    <measurement group_id="O4" value="0.9" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.79"/>
                    <measurement group_id="O2" value="0.9" spread="0.75"/>
                    <measurement group_id="O3" value="0.8" spread="0.54"/>
                    <measurement group_id="O4" value="1.1" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.76"/>
                    <measurement group_id="O2" value="0.8" spread="0.73"/>
                    <measurement group_id="O3" value="0.7" spread="0.56"/>
                    <measurement group_id="O4" value="1.0" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eyelid Swelling at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Eyelid Swelling at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.60"/>
                    <measurement group_id="O2" value="0.7" spread="0.54"/>
                    <measurement group_id="O3" value="0.9" spread="0.68"/>
                    <measurement group_id="O4" value="0.7" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.70"/>
                    <measurement group_id="O2" value="0.8" spread="0.73"/>
                    <measurement group_id="O3" value="0.9" spread="0.82"/>
                    <measurement group_id="O4" value="0.9" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.69"/>
                    <measurement group_id="O2" value="0.8" spread="0.76"/>
                    <measurement group_id="O3" value="0.9" spread="0.72"/>
                    <measurement group_id="O4" value="0.9" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eyelid Swelling at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Eyelid Swelling at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.56"/>
                    <measurement group_id="O2" value="0.5" spread="0.70"/>
                    <measurement group_id="O3" value="0.5" spread="0.49"/>
                    <measurement group_id="O4" value="0.7" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.68"/>
                    <measurement group_id="O2" value="0.6" spread="0.65"/>
                    <measurement group_id="O3" value="0.6" spread="0.65"/>
                    <measurement group_id="O4" value="0.8" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.71"/>
                    <measurement group_id="O2" value="0.6" spread="0.58"/>
                    <measurement group_id="O3" value="0.5" spread="0.49"/>
                    <measurement group_id="O4" value="0.7" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tearing at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Tearing at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.07"/>
                    <measurement group_id="O2" value="0.8" spread="0.72"/>
                    <measurement group_id="O3" value="0.6" spread="0.51"/>
                    <measurement group_id="O4" value="0.6" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.89"/>
                    <measurement group_id="O2" value="0.5" spread="0.64"/>
                    <measurement group_id="O3" value="0.7" spread="0.65"/>
                    <measurement group_id="O4" value="0.9" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.85"/>
                    <measurement group_id="O2" value="0.4" spread="0.63"/>
                    <measurement group_id="O3" value="0.7" spread="0.62"/>
                    <measurement group_id="O4" value="0.9" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tearing at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Tearing at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.78"/>
                    <measurement group_id="O2" value="0.7" spread="0.61"/>
                    <measurement group_id="O3" value="0.6" spread="0.75"/>
                    <measurement group_id="O4" value="0.8" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.79"/>
                    <measurement group_id="O2" value="0.6" spread="0.54"/>
                    <measurement group_id="O3" value="0.7" spread="0.66"/>
                    <measurement group_id="O4" value="0.8" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.77"/>
                    <measurement group_id="O2" value="0.5" spread="0.53"/>
                    <measurement group_id="O3" value="0.7" spread="0.72"/>
                    <measurement group_id="O4" value="0.7" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tearing at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Tearing at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.74"/>
                    <measurement group_id="O2" value="0.5" spread="0.49"/>
                    <measurement group_id="O3" value="0.3" spread="0.56"/>
                    <measurement group_id="O4" value="0.6" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.66"/>
                    <measurement group_id="O2" value="0.5" spread="0.50"/>
                    <measurement group_id="O3" value="0.4" spread="0.50"/>
                    <measurement group_id="O4" value="0.6" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.60"/>
                    <measurement group_id="O2" value="0.4" spread="0.47"/>
                    <measurement group_id="O3" value="0.2" spread="0.33"/>
                    <measurement group_id="O4" value="0.6" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhinorrhea at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Rhinorrhea at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.26"/>
                    <measurement group_id="O2" value="0.4" spread="0.49"/>
                    <measurement group_id="O3" value="0.7" spread="0.99"/>
                    <measurement group_id="O4" value="0.7" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.01"/>
                    <measurement group_id="O2" value="0.6" spread="0.77"/>
                    <measurement group_id="O3" value="1.1" spread="1.04"/>
                    <measurement group_id="O4" value="1.0" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.14"/>
                    <measurement group_id="O2" value="0.7" spread="0.80"/>
                    <measurement group_id="O3" value="1.1" spread="1.05"/>
                    <measurement group_id="O4" value="1.1" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhinorrhea at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Rhinorrhea at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.28"/>
                    <measurement group_id="O2" value="0.6" spread="0.65"/>
                    <measurement group_id="O3" value="0.8" spread="0.90"/>
                    <measurement group_id="O4" value="0.7" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.29"/>
                    <measurement group_id="O2" value="0.7" spread="0.69"/>
                    <measurement group_id="O3" value="1.2" spread="0.91"/>
                    <measurement group_id="O4" value="1.0" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.28"/>
                    <measurement group_id="O2" value="0.6" spread="0.70"/>
                    <measurement group_id="O3" value="1.0" spread="0.71"/>
                    <measurement group_id="O4" value="0.8" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhinorrhea at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Rhinorrhea at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.20"/>
                    <measurement group_id="O2" value="0.2" spread="0.41"/>
                    <measurement group_id="O3" value="0.3" spread="0.58"/>
                    <measurement group_id="O4" value="0.6" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.25"/>
                    <measurement group_id="O2" value="0.4" spread="0.65"/>
                    <measurement group_id="O3" value="0.5" spread="0.75"/>
                    <measurement group_id="O4" value="0.8" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.23"/>
                    <measurement group_id="O2" value="0.4" spread="0.71"/>
                    <measurement group_id="O3" value="0.5" spread="0.68"/>
                    <measurement group_id="O4" value="0.6" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Pruritus at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Pruritus at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.91"/>
                    <measurement group_id="O2" value="0.2" spread="0.37"/>
                    <measurement group_id="O3" value="0.5" spread="0.65"/>
                    <measurement group_id="O4" value="0.4" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.91"/>
                    <measurement group_id="O2" value="0.4" spread="0.65"/>
                    <measurement group_id="O3" value="0.7" spread="0.80"/>
                    <measurement group_id="O4" value="0.8" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.99"/>
                    <measurement group_id="O2" value="0.6" spread="0.91"/>
                    <measurement group_id="O3" value="0.6" spread="0.65"/>
                    <measurement group_id="O4" value="0.8" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Pruritus at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Pruritus at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.93"/>
                    <measurement group_id="O2" value="0.4" spread="0.64"/>
                    <measurement group_id="O3" value="0.4" spread="0.58"/>
                    <measurement group_id="O4" value="0.4" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.03"/>
                    <measurement group_id="O2" value="0.4" spread="0.58"/>
                    <measurement group_id="O3" value="0.8" spread="0.93"/>
                    <measurement group_id="O4" value="0.6" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.90"/>
                    <measurement group_id="O2" value="0.5" spread="0.65"/>
                    <measurement group_id="O3" value="0.6" spread="0.82"/>
                    <measurement group_id="O4" value="0.7" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Pruritus at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Pruritus at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.99"/>
                    <measurement group_id="O2" value="0.2" spread="0.37"/>
                    <measurement group_id="O3" value="0.3" spread="0.56"/>
                    <measurement group_id="O4" value="0.4" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.84"/>
                    <measurement group_id="O2" value="0.3" spread="0.56"/>
                    <measurement group_id="O3" value="0.2" spread="0.44"/>
                    <measurement group_id="O4" value="0.4" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.95"/>
                    <measurement group_id="O2" value="0.4" spread="0.64"/>
                    <measurement group_id="O3" value="0.3" spread="0.66"/>
                    <measurement group_id="O4" value="0.4" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ear or Palate Pruritus at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ear or Palate Pruritus at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.87"/>
                    <measurement group_id="O2" value="0.4" spread="0.57"/>
                    <measurement group_id="O3" value="0.3" spread="0.74"/>
                    <measurement group_id="O4" value="0.5" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.09"/>
                    <measurement group_id="O2" value="0.8" spread="0.90"/>
                    <measurement group_id="O3" value="0.5" spread="0.77"/>
                    <measurement group_id="O4" value="1.0" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.11"/>
                    <measurement group_id="O2" value="0.9" spread="0.91"/>
                    <measurement group_id="O3" value="0.8" spread="0.93"/>
                    <measurement group_id="O4" value="1.2" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ear or Palate Pruritus at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ear or Palate Pruritus at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.89"/>
                    <measurement group_id="O2" value="0.3" spread="0.46"/>
                    <measurement group_id="O3" value="0.4" spread="0.76"/>
                    <measurement group_id="O4" value="0.5" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.96"/>
                    <measurement group_id="O2" value="0.6" spread="0.65"/>
                    <measurement group_id="O3" value="0.7" spread="0.98"/>
                    <measurement group_id="O4" value="0.8" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.11"/>
                    <measurement group_id="O2" value="0.7" spread="0.74"/>
                    <measurement group_id="O3" value="0.7" spread="0.90"/>
                    <measurement group_id="O4" value="0.7" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.99"/>
                    <measurement group_id="O2" value="0.2" spread="0.52"/>
                    <measurement group_id="O3" value="0.3" spread="0.56"/>
                    <measurement group_id="O4" value="0.4" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="08" spread="0.95"/>
                    <measurement group_id="O2" value="0.4" spread="0.76"/>
                    <measurement group_id="O3" value="0.3" spread="0.58"/>
                    <measurement group_id="O4" value="0.7" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.01"/>
                    <measurement group_id="O2" value="0.5" spread="0.77"/>
                    <measurement group_id="O3" value="0.3" spread="0.58"/>
                    <measurement group_id="O4" value="0.7" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Congestion at Onset of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Congestion at Onset of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.99"/>
                    <measurement group_id="O2" value="0.5" spread="0.65"/>
                    <measurement group_id="O3" value="0.8" spread="1.18"/>
                    <measurement group_id="O4" value="0.8" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.04"/>
                    <measurement group_id="O2" value="0.6" spread="0.76"/>
                    <measurement group_id="O3" value="1.0" spread="1.19"/>
                    <measurement group_id="O4" value="1.2" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.05"/>
                    <measurement group_id="O2" value="0.8" spread="0.99"/>
                    <measurement group_id="O3" value="1.0" spread="1.14"/>
                    <measurement group_id="O4" value="1.3" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Congestion at Duration of Action (24 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Congestion at Duration of Action (24 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.97"/>
                    <measurement group_id="O2" value="0.6" spread="0.58"/>
                    <measurement group_id="O3" value="0.8" spread="0.80"/>
                    <measurement group_id="O4" value="0.7" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.98"/>
                    <measurement group_id="O2" value="0.6" spread="0.58"/>
                    <measurement group_id="O3" value="1.2" spread="0.94"/>
                    <measurement group_id="O4" value="1.1" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.00"/>
                    <measurement group_id="O2" value="0.6" spread="0.65"/>
                    <measurement group_id="O3" value="1.1" spread="1.04"/>
                    <measurement group_id="O4" value="1.2" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Congestion at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Congestion at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.05"/>
                    <measurement group_id="O2" value="0.4" spread="0.58"/>
                    <measurement group_id="O3" value="0.4" spread="0.59"/>
                    <measurement group_id="O4" value="0.8" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.08"/>
                    <measurement group_id="O2" value="0.5" spread="0.65"/>
                    <measurement group_id="O3" value="0.4" spread="0.59"/>
                    <measurement group_id="O4" value="1.4" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.14"/>
                    <measurement group_id="O2" value="0.5" spread="0.65"/>
                    <measurement group_id="O3" value="0.4" spread="0.59"/>
                    <measurement group_id="O4" value="1.4" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Composite Score at Duration of Action (16 Hours Post-dose)</title>
        <description>A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Composite Score at Duration of Action (16 Hours Post-dose)</title>
          <description>A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.</description>
          <population>Intent to Treat (ITT)</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="52.4"/>
                    <measurement group_id="O4" value="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="79.2"/>
                    <measurement group_id="O3" value="90.5"/>
                    <measurement group_id="O4" value="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="95.2"/>
                    <measurement group_id="O4" value="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Composite Score at Duration of Action (24 Hours Post-dose)</title>
        <description>A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Composite Score at Duration of Action (24 Hours Post-dose)</title>
          <description>A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.</description>
          <population>Intent to Treat (ITT)</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                    <measurement group_id="O2" value="76.0"/>
                    <measurement group_id="O3" value="85.7"/>
                    <measurement group_id="O4" value="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="84.0"/>
                    <measurement group_id="O3" value="90.5"/>
                    <measurement group_id="O4" value="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="88.0"/>
                    <measurement group_id="O3" value="81.0"/>
                    <measurement group_id="O4" value="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Composite Score at Onset of Action (15 Minutes Post-dose)</title>
        <description>A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Composite Score at Onset of Action (15 Minutes Post-dose)</title>
          <description>A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.</description>
          <population>Intent to Treat (ITT)</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="47.6"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="47.6"/>
                    <measurement group_id="O4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="52.4"/>
                    <measurement group_id="O4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of Study Medication at Visit 3A</title>
        <description>Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome..</description>
        <time_frame>upon instillation, 1 minute and 2 minutes post instillation</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.05%</title>
            <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0.1%</title>
            <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O3">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
          <group group_id="O4">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Study Medication at Visit 3A</title>
          <description>Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome..</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upon instillation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.95"/>
                    <measurement group_id="O2" value="0.7" spread="1.04"/>
                    <measurement group_id="O3" value="1.3" spread="1.93"/>
                    <measurement group_id="O4" value="0.6" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute post-instillation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.13"/>
                    <measurement group_id="O2" value="0.9" spread="1.13"/>
                    <measurement group_id="O3" value="2.0" spread="2.25"/>
                    <measurement group_id="O4" value="0.9" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 minutes post-instillation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.10"/>
                    <measurement group_id="O2" value="1.0" spread="1.18"/>
                    <measurement group_id="O3" value="1.7" spread="2.27"/>
                    <measurement group_id="O4" value="0.6" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed through study completion, approximately two months. All subjects who received study medication were evaluable for the safety analysis.</time_frame>
      <desc>Throughout the visits, staff collected all Adverse Events reported, elicited or observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>AC-170 0.05%</title>
          <description>AC-170 0.05%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
        <group group_id="E2">
          <title>AC-170 0.1%</title>
          <description>AC-170 0.1%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
        <group group_id="E3">
          <title>AC-170 0.24%</title>
          <description>AC-170 0.24%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
        <group group_id="E4">
          <title>AC-170 0%</title>
          <description>AC-170 0%: 1 drop in each eye at 3 separate times during a 21 day period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Visual acuity reducsed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Palatal Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael V.W. Bergamini, PhD - Chief Scientific Officer/Executive Vice President</name_or_title>
      <organization>Nicox Ophthalmics Inc.</organization>
      <phone>817-529-9315</phone>
      <email>bergamini@nicox.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

